Short Interest in Tema Oncology ETF (NASDAQ:CANC) Increases By 79.6%

Tema Oncology ETF (NASDAQ:CANC) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 27,461 shares, a growth of 79.6% from the June 15th total of 15,293 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily trading volume, of 67,600 shares, the days-to-cover ratio is currently 0.4 days.

Tema Oncology ETF Trading Down 1.0%

Shares of CANC stock opened at $40.51 on Friday. The company’s fifty day moving average price is $38.69 and its 200-day moving average price is $37.45. The stock has a market cap of $192.02 million, a PE ratio of 20.39 and a beta of 0.67. Tema Oncology ETF has a 12 month low of $25.12 and a 12 month high of $42.63.

Institutional Investors Weigh In On Tema Oncology ETF

Several hedge funds have recently bought and sold shares of CANC. Thrivent Financial for Lutherans grew its holdings in Tema Oncology ETF by 891.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock worth $50,747,000 after purchasing an additional 1,314,177 shares during the period. Jane Street Group LLC bought a new position in shares of Tema Oncology ETF during the fourth quarter valued at approximately $1,100,000. Flow Traders U.S. LLC purchased a new position in shares of Tema Oncology ETF during the third quarter valued at approximately $630,000. LPL Financial LLC purchased a new position in shares of Tema Oncology ETF during the fourth quarter valued at approximately $278,000. Finally, Roxbury Financial LLC boosted its position in shares of Tema Oncology ETF by 326.4% in the 2nd quarter. Roxbury Financial LLC now owns 3,940 shares of the company’s stock worth $162,000 after purchasing an additional 3,016 shares in the last quarter.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.